药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Carlumab
The risk or severity of adverse effects can be increased when Carlumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Intetumumab
The risk or severity of adverse effects can be increased when Intetumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ibalizumab
The risk or severity of adverse effects can be increased when Ibalizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lumretuzumab
The risk or severity of adverse effects can be increased when Lumretuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tovetumab
The risk or severity of adverse effects can be increased when Tovetumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dacetuzumab
The risk or severity of adverse effects can be increased when Dacetuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bimagrumab
The risk or severity of adverse effects can be increased when Bimagrumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Blosozumab
The risk or severity of adverse effects can be increased when Blosozumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Mavrilimumab
The risk or severity of adverse effects can be increased when Mavrilimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Inebilizumab
The risk or severity of adverse effects can be increased when Inebilizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Plozalizumab
The risk or severity of adverse effects can be increased when Plozalizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Mogamulizumab
The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Mirvetuximab Soravtansine
The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bococizumab
The risk or severity of adverse effects can be increased when Bococizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Indusatumab vedotin
The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fresolimumab
The risk or severity of adverse effects can be increased when Fresolimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Dusigitumab
The risk or severity of adverse effects can be increased when Dusigitumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Fezakinumab
The risk or severity of adverse effects can be increased when Fezakinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ensituximab
The risk or severity of adverse effects can be increased when Ensituximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tanezumab
The risk or severity of adverse effects can be increased when Tanezumab is combined with Belantamab mafodotin.